Genmab (NASDAQ:GMAB) 주식

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Genmab AS

Ecovyst plans to fund the acquisition with cash on hand, and the transaction is targeted to close in the second quarter of 2025, subject to customary closing conditions.&nbsp;

ECVT

Ecovyst Reaches Agreement To Acquire Sulfuric Acid Production Assets Of Cornerstone Chemical Company Located In Waggaman, Louisiana; No Terms Disclosed

NBIS

Nebius To Be An Early Adopter AI Cloud Provider To Offer The New NVIDIA Blackwell Ultra AI Factory Platform

The completion of the merger remains subject to the approval of CGFI shareholders and is expected to occur in the second quarter of 2025.

First Commonwealth Financial Receives All Regulatory Approvals Required To Complete CenterGroup Merger

Guidance

BSLK

Bolt Projects Expects At Least $4.5M In Revenues For 2025 And At Least $9M  For 2026

Earnings

Bolt Projects Holdings Q4 EPS $(0.19) Vs. $(2.13) YoY, Sales $1.3M Down From $1.4M YoY

<h3>Gainers</h3>
<ul>
<li>Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) shares moved upwards by 36.7% to $2.87 during Tuesday's after-market session. The market value of their outstanding shares is at $25.1 million. The company's, Q4 earnings came out today. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGB#NASDAQ">QVCGB</a>) stock increased by 6.29% to $6.25. The market value of their outstanding shares is at $2.4 billion. </li>
<li>REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) shares increased by 5.63% to $4.5. The company's market cap stands at $87.6 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) stock moved upwards by 5.32% to $0.55. The company's market cap stands at $4.3 million. </li>
<li>Cenntro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENN#NASDAQ">CENN</a>) shares moved upwards by 4.99% to $1.0. The company's market cap stands at $30.7 million. </li>
<li>Neo-Concept International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) stock rose 4.99% to $0.41. The market value of their outstanding shares is at $8.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Chijet Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) shares decreased by 16.7% to $1.35 during Tuesday's after-market session. The market value of their outstanding shares is at $9.4 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) shares decreased by 9.56% to $0.34. The company's market cap stands at $3.3 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares fell 8.4% to $0.45. The market value of their outstanding shares is at $127.6 million. </li>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock decreased by 5.84% to $0.61. The company's market cap stands at $12.3 million. </li>
<li>Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) shares decreased by 5.01% to $0.85. The market value of their outstanding shares is at $92.9 million. </li>
<li>Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) stock declined by 4.97% to $1.34. The company's market cap stands at $18.2 million. The company's, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATER

BRLT

CENN

CJET

FTEL

GORV

NWTN

QVCGB

TCTM

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

HealthEquity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported fourth-quarter financial results after the market close on Tuesday and shares are sinking. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/03/g44384524/healthequity-reports-fiscal-year-and-fourth-quarter-ended-january-31-2025-financial-results">of the report</a>.
<ul>
<li>Q4 Revenue: $311.82 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $306.05 million</li>
</ul>
<ul>
<li>Q4 Adjusted EPS: 69 cents, versus estimates of 72 cents</li>
</ul>
Total revenue was up 19% on a year-over-year basis. The company reported 9.9 million health savings accounts (HSAs) as of Jan. 31, up 14% year-over-year. Total accounts came in at 17 million as of Jan. 31. Total HSA assets were up 27% year-over-year to $32.1 billion.
HealthEquity said it repurchased 1.4 million shares of its common stock in fiscal 2025 for $122.2 million. The company had $177.8 million remaining under its buyback as of Jan. 31.
&#8220;Team Purple finished fiscal ‘25 in strong fashion, with record revenues and major strides in advancing our strategic initiatives, allowing us to provide our&nbsp;outlook&nbsp;for an even stronger fiscal ‘26,&#8221; said Scott Cutler, president and CEO of HealthEquity. 
&#8220;With a focus on Member First Secure Mobile Experiences, we are executing against our 3Ds strategy to Deepen partnerships, Deliver remarkable experiences, and Drive member outcomes for our Clients, Network Partners, and members.&#8221;
Outlook: HealthEquity expects fiscal year 2026 revenue of $1.28 billion to $1.305 billion versus estimates of $1.301 billion. The company anticipates full-year earnings of $3.57 to $3.74 per share versus estimates of $3.71 per share.
The guidance came in below estimates at the midpoint, which appears to be weighing on shares after hours.
HealthEquity executives will further discuss the quarter on a call with investors and analysts at 4:30 p.m. ET.
HQY Price Action: <a href="http://benzinga.com/quote/hqy">HealthEquity shares</a> were down 12.46% after hours, trading at $89 at the time of publication Tuesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44385576/five-below-q4-earnings-preview-analyst-less-optimistic-due-to-macro-tariffs-and-short-holiday-season">Five Below Q4 Earnings Preview: Analyst Less Optimistic Due To Macro, Tariffs And Short Holiday Season</a></li>
</ul>
Photo: Shutterstock.

Health Care

Analyst Ratings

Insurance

HealthEquity Stock Falls After Reporting Q4 Results: Revenue Beat, EPS Miss, Soft Guidance

<h3>Gainers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares moved upwards by 28.9% to $0.17 during Tuesday's after-market session. The company's market cap stands at $3.0 million. </li>
<li>Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) shares increased by 19.99% to $4.56. The market value of their outstanding shares is at $209.9 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares rose 14.88% to $1.09. The company's market cap stands at $16.7 million. </li>
<li>Pulmatrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PULM#NASDAQ">PULM</a>) shares moved upwards by 12.02% to $8.29. The company's market cap stands at $30.2 million. </li>
<li>OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) shares increased by 8.46% to $3.46. The market value of their outstanding shares is at $418.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock increased by 6.91% to $1.7. The company's market cap stands at $14.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) stock fell 12.3% to $89.15 during Tuesday's after-market session. The market value of their outstanding shares is at $7.7 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 10.57% to $28.26. The company's market cap stands at $367.7 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) stock declined by 9.6% to $0.7. The market value of their outstanding shares is at $29.0 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock declined by 7.26% to $11.5. The company's market cap stands at $34.9 million. </li>
<li>Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) stock declined by 7.1% to $2.88. The company's market cap stands at $330.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Savara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) stock decreased by 6.63% to $2.62. The market value of their outstanding shares is at $449.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

ADGM

CRGX

OABI

PULM

RLYB

SCNX

SVRA

VRPX

XCUR

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) shares increased by 10.3% to $9.4 during Tuesday's after-market session. The company's market cap stands at $228.5 million. </li>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) stock rose 7.29% to $4.12. The market value of their outstanding shares is at $63.8 million. As per the news, the Q4 earnings report came out today. </li>
<li>Primega Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares increased by 7.01% to $0.67. The market value of their outstanding shares is at $16.0 million. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock rose 6.43% to $0.22. The company's market cap stands at $12.0 million. </li>
<li>Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) stock moved upwards by 5.26% to $0.92. The company's market cap stands at $86.3 million. </li>
<li>Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) shares moved upwards by 5.16% to $3.26. The company's market cap stands at $970.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) shares fell 10.7% to $0.23 during Tuesday's after-market session. The company's market cap stands at $10.2 million. </li>
<li>Captivision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPT#NASDAQ">CAPT</a>) shares fell 5.37% to $0.6. The market value of their outstanding shares is at $19.5 million. </li>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) shares declined by 5.36% to $1.06. The company's market cap stands at $17.2 million. </li>
<li>Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) shares fell 4.34% to $0.32. The market value of their outstanding shares is at $9.6 million. </li>
<li>Huachen AI Parking Mgmt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAI#NASDAQ">HCAI</a>) shares decreased by 4.33% to $7.78. The company's market cap stands at $246.7 million. </li>
<li>Roma Green Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROMA#NASDAQ">ROMA</a>) shares declined by 4.26% to $0.77. The market value of their outstanding shares is at $11.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPT

DXST

EVEX

HCAI

Nuveen Insured California Premium Fund Ii

PGHL

PITA

ROMA

SPIR

SRFM

WATT

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) stock increased by 6.4% to $1.17 during Tuesday's after-market session. The market value of their outstanding shares is at $1.6 million. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) stock rose 6.0% to $0.55. The market value of their outstanding shares is at $10.3 million. </li>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock rose 5.7% to $0.78. The company's market cap stands at $17.9 million. </li>
<li>Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) stock increased by 4.9% to $6.42. The market value of their outstanding shares is at $408.7 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) stock rose 4.43% to $0.94. The market value of their outstanding shares is at $34.7 million. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) stock increased by 4.35% to $0.21. The company's market cap stands at $14.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares declined by 8.9% to $0.36 during Tuesday's after-market session. The market value of their outstanding shares is at $16.6 million. </li>
<li>SatixFy Communications (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SATX#AMEX">SATX</a>) shares decreased by 4.93% to $1.34. The company's market cap stands at $112.0 million. </li>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock declined by 4.6% to $0.38. The company's market cap stands at $24.2 million. </li>
<li>Arqit Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) stock declined by 4.39% to $19.39. The market value of their outstanding shares is at $247.1 million. </li>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) stock decreased by 4.12% to $4.6. The market value of their outstanding shares is at $8.0 million. </li>
<li>Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) stock decreased by 4.07% to $33.26. The company's market cap stands at $5.2 billion. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBK

ARQQ

GRYP

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MOBX

ORKT

SatixFy Communications Ltd. Ordinary Share

SATX

VERX

XTKG

12 Information Technology Stocks Moving In Tuesday's After-Market Session

The use of Oracle Cloud Isolated Region will transform the Command, Control, Communications and Computers (C4) functions of the SAF, and will modernize its digital capabilities with increased scalability and performance.

Contracts

ORCL

Singapore's Defence Science And Technology Agency Signs Contract With Oracle For An Oracle Cloud Isolated Region

Google parent Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) announced on Tuesday that it has signed an agreement to acquire cloud security platform Wiz for $32 billion. Experts weigh in on Google's<a href="https://www.benzinga.com/tech/25/03/44376743/google-parent-alphabet-to-acquire-wiz-in-32-billion-deal-its-biggest-bet-yet"> largest acquisition ever.&nbsp;</a>
Expert Ideas: J.P. Morgan analyst Doug Anmuth sees the Wiz acquisition as strengthening Google's cybersecurity suit and allowing for safer and more efficient multicloud operations.  
"We believe the Wiz acquisition will further strengthen Google's multicloud value proposition &amp; deepen its enterprise relationships as Wiz is used by over 50% of Fortune 100 companies," the analyst wrote.&nbsp;&nbsp;
Read Next: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/03/44367584/black-swan-hedge-fund-posts-4000-profits-during-covid-19-market-crash-heres-how">&#8216;Black Swan&#8217; Hedge Fund Posts 4,000% Profits During COVID-19 Market Crash: Here&#8217;s How</a>
Anmuth noted the expected closing date for the deal is 2026 and believes the longer-than-usual closing reflects the regulatory scrutiny the acquisition will face. He sees the deal as a type of bellwether for the Trump administration's tolerance for large-scale mergers and acquisitions, which will have broader implications for other large-cap tech companies. 
&#8220;This deal will get careful scrutiny,&#8221; Michael Carrier, an antitrust law professor at Rutgers Law School, told Yahoo Finance.&nbsp;
&#8220;But at the end of the day, I believe it is likely to be approved given an anticipated less aggressive blocking of mergers and the AI angle,&#8221; Carrier added.&nbsp;
GOOG shares fell 2.34% on Tuesday following the announcement of the deal, which is Google's largest ever and also the largest ever in the cybersecurity sector.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/events/25/03/44380519/soundhound-ai-at-2025-nvidia-gpu-technology-conference-in-car-voice-commerce-ecosystem-a-game-changer-for-automotivetech">SoundHound AI At 2025 NVIDIA GPU Technology Conference: In-car Voice Commerce Ecosystem &#8216;A Game-Changer For #AutomotiveTech&#8217;&nbsp;</a></li>
</ul>
Image: Shutterstock

Tech

GOOG

GOOGL

Google's Wiz Acquisition Strengthens Cybersecurity Suite, Adds To 'Multicloud Value Proposition': Analyst

Ratings for Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $120.07, a high estimate of $137.00, and a low estimate of $109.00. Observing a 3.51% increase, the current average has risen from the previous average price target of $116.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1742331670_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Oshkosh. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$117.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Ross Gilardi</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$127.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Tim Thein</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$118.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$113.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$109.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$116.00</td>
<td>$113.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Oshkosh. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Oshkosh compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Oshkosh's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Oshkosh's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OSK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Oshkosh analyst ratings.</a>
<h2>About Oshkosh</h2>
Oshkosh Corp is the top producer of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, where it is typically the market share leader in North America, or, in the case of JLG aerial work platforms. The company had manufactured joint light tactical vehicles for the U.S. Department of Defense. The company reports in three segments: Access, Vocational and Defense. It derives maximum revenue from Access Segment.
<h3>Oshkosh's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Oshkosh's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 5.32%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Oshkosh's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Oshkosh's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.71%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Oshkosh's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.59% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Oshkosh's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.23.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Oshkosh Stock

Analysts' ratings for Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Getty Images Holdings, revealing an average target of $5.49, a high estimate of $7.70, and a low estimate of $3.75. This current average represents a 6.31% decrease from the previous average price target of $5.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1742331658_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Getty Images Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Pachter</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$7.70</td>
<td>$7.70</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$4.50</td>
<td>$6.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$3.75</td>
<td>$3.75</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Getty Images Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Getty Images Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Getty Images Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Getty Images Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GETY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Getty Images Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Getty Images Holdings</h2>
Getty Images Holdings Inc is engaged in the core mission of bringing the world's creative and editorial visual content solutions to its customers to engage their audiences. the company has developed market enhancements across e-commerce, content subscriptions, user-generated content, diverse and inclusive content, and proprietary research alongside investment in its technology platform, which includes artificial intelligence and machine learning-driven search functionality and image editing and integrated APIs, to become a trusted industry leader in the visual content. Geographically the company operates in the Americas, Europe, the Middle East, Africa, and Asia-Pacific, out of which a majority of its revenue is generated from the Americas.
<h3>Getty Images Holdings: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Getty Images Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.91% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Getty Images Holdings's net margin is impressive, surpassing industry averages. With a net margin of -0.91%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Getty Images Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.33% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Getty Images Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.09%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 2.04, Getty Images Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GETY

What Analysts Are Saying About Getty Images Holdings Stock

In the latest quarter, 18 analysts provided ratings for GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $435.22, a high estimate of $500.00, and a low estimate of $374.00. This upward trend is apparent, with the current average reflecting a 4.75% increase from the previous average price target of $415.47.
<img src="https://www.benzinga.com/files/images/story/2025/1742331647_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive GE Vernova is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$445.00</td>
<td>$453.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$380.00</td>
<td>-</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$420.00</td>
<td>$471.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$427.00</td>
<td>$487.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$448.00</td>
<td>-</td>
</tr>
<tr>
<td>Martin Malloy</td>
<td>Johnson Rice</td>
<td>Announces</td>
<td>Buy</td>
<td>$425.00</td>
<td>-</td>
</tr>
<tr>
<td>Christopher Dendrinos</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$453.00</td>
<td>$453.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$446.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$470.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$471.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$437.00</td>
<td>$361.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$487.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$436.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$446.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$420.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$374.00</td>
<td>$367.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to GE Vernova. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of GE Vernova compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of GE Vernova's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into GE Vernova's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GEV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GE Vernova analyst ratings.</a>
<h2>Discovering GE Vernova: A Closer Look</h2>
GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.
<h3>Breaking Down GE Vernova's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: GE Vernova's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 5.11%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: GE Vernova's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.58% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): GE Vernova's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.08% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): GE Vernova's ROA stands out, surpassing industry averages. With an impressive ROA of 0.95%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.11, GE Vernova adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 18 Analyst Projections For GE Vernova

Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $29.75, a high estimate of $33.00, and a low estimate of $28.00. Highlighting a 3.25% decrease, the current average has fallen from the previous average price target of $30.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1742331640_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Pfizer among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Andrew Baum</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pfizer. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pfizer compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Pfizer's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Pfizer's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PFE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pfizer analyst ratings.</a>
<h2>Delving into Pfizer's Background</h2>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
<h3>Pfizer: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Pfizer's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 21.93% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Pfizer's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 2.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.45%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Pfizer's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.19%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Pfizer's debt-to-equity ratio is below the industry average at 0.72, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess Pfizer: What You Need To Know

Ratings for Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) were provided by 38 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">14</td>
<td align="right">22</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">13</td>
<td align="right">15</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $754.92, a high estimate of $935.00, and a low estimate of $610.00. Observing a 8.57% increase, the current average has risen from the previous average price target of $695.34. 
<img src="https://www.benzinga.com/files/images/story/2025/1742331628_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Meta Platforms is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$710.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$935.00</td>
<td>$645.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$786.00</td>
<td>$736.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$780.00</td>
<td>$753.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$800.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$765.00</td>
<td>$710.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$610.00</td>
<td>$530.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$800.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$800.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$765.00</td>
<td>$688.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$820.00</td>
<td>$820.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$790.00</td>
<td>$720.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$770.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$800.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$627.00</td>
<td>$583.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$750.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$800.00</td>
<td>$725.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$750.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$775.00</td>
<td>$670.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$846.00</td>
<td>$811.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$705.00</td>
<td>$630.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$752.00</td>
<td>$685.00</td>
</tr>
<tr>
<td>Jeffrey Wlodarczak</td>
<td>Pivotal Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$875.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$750.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$750.00</td>
<td>$680.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$750.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$750.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$811.00</td>
<td>$811.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$700.00</td>
<td>$680.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$720.00</td>
<td>$730.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$725.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$660.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$685.00</td>
<td>$641.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$700.00</td>
<td>$655.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$715.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$680.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Wolfe Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$730.00</td>
<td>$670.00</td>
</tr>
<tr>
<td>Matthew Condon</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$750.00</td>
<td>$660.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Meta Platforms. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Meta Platforms compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Meta Platforms's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Meta Platforms's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/META/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Meta Platforms analyst ratings.</a>
<h2>About Meta Platforms</h2>
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
<h3>A Deep Dive into Meta Platforms's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Meta Platforms's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.63% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Meta Platforms's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 43.07% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Meta Platforms's ROE excels beyond industry benchmarks, reaching 12.0%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Meta Platforms's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.83% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Meta Platforms's debt-to-equity ratio is below the industry average at 0.27, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Meta Platforms: Insights From 38 Analyst Reviews

In the latest quarter, 7 analysts provided ratings for Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Align Technology and provided 12-month price targets. The average target is $261.71, accompanied by a high estimate of $280.00 and a low estimate of $235.00. Experiencing a 0.93% decline, the current average is now lower than the previous average price target of $264.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1742331615_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Align Technology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$255.00</td>
<td>-</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$272.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$260.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$235.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Align Technology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Align Technology compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Align Technology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Align Technology's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Align Technology analyst ratings.</a>
<h2>About Align Technology</h2>
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
<h3>Key Indicators: Align Technology's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Align Technology's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 4.02%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Align Technology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 10.43%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.66%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Align Technology's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.65% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGN

Beyond The Numbers: 7 Analysts Discuss Align Technology Stock

Nicknamed "Larry," a 560-pound Twitter blue bird logo from the San Francisco headquarters is up for auction. Elon Musk secured the item as part of an online yard sale of sorts, after he acquired and<a href="https://www.benzinga.com/news/23/08/33858895/twitters-auction-encore-how-to-bid-on-apple-devices-obama-art-and-classic-blue-birds-straight-from-h"> renamed the company.</a>
What Happened: Musk<a href="https://www.benzinga.com/news/23/04/31810229/elon-musk-bought-twitter-1-year-ago-a-look-back-at-whats-happened-since-and-what-could-be-next"> paid $44 billion</a> to acquire Twitter in 2022. He later renamed the company X, and <a href="https://www.benzinga.com/news/23/07/33400999/musks-unprecedented-rebrand-of-twitter-to-x-could-cost-100-million-trademark-specialist-labels-it-th">changed the company's logo</a>.
While many still call the social media platform Twitter, their messages on the app tweets, the official Twitter name and blue bird logo is dead to Musk and the company.
As spotted by <a href="https://www.engadget.com/social-media/the-560-pound-twitter-logo-from-its-san-francisco-headquarters-is-up-for-auction-180326992.html?src=rss">Engadget</a>, RR Auctions is <a href="https://www.rrauction.com/auctions/lot-detail/349988607146320-twitter-inc-official-bird-logo-fascia-sign-an-iconic-fixture-from-the-companys-market-square-headquarters-in-san-francisco/">auctioning </a>off the 12-foot-tall by eight-foot-long logo that previously adorned the San Francisco headquarters. The sign is one of two birds that was previously located at the headquarters on Market Street.
"Incredible official Twitter Inc. ‘bird log' fascia sign formerly displayed on the exterior of the social media giant's San Francisco headquarters – obtained from Elon Musk's ‘rebranding auction' in September 2023," the auction listing reads.
According to the listing, the company nicknamed the logo Larry after former NBA great Larry Bird.
At the time of writing, the high bid is at $21,664 with the auction set to end on Aug. 20. RR Auctions has an estimated value of $40,000 for the listing, suggesting bids could nearly double in the coming days. 
The auction winner will be responsible for the costs of moving the sign from a storage facility in San Francisco.
The auction includes a YouTube video showing the work done to remove the logo from the building, including a crane and multiple workers.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: After the rebranding, Musk decided to sell off many old Twitter logos and office products.
Among the most coveted were the large Twitter logos. A large Twitter logo from inside the office sold for $100,000. The outside logos sold for undisclosed prices.
While the company has a new name and logo, the iconic Twitter logo and blue bird memorabilia could become sought after by collectors for years, similar to<a href="https://www.benzinga.com/news/25/02/43926987/steve-jobs-signed-apple-business-card-valued-at-60000-sells-for-much-more-at-auction-heres-the-winning-bid"> old business cards,</a> magazines and autographs of top technology CEOs and founders.
<a href="https://www.benzinga.com/25/02/44022369/exclusive-if-x-went-public-today-would-it-be-worth-75-billion-or-less-than-20-billion-poll-says-this-amount">Benzinga recently asked </a>about what the valuation of the privately held company should be.
&#8220;What do you believe is a fair valuation for X (formerly Twitter)?&#8221; Benzinga asked.
The results were:
<ul>
<li>Less than $20 Billion: 45%</li>
<li>$41-$75 Billion: 24%</li>
<li>Over $75 Billion: 16%</li>
<li>$21-$40 Billion: 15%</li>
</ul>
Nearly half of the voters in the poll said X should be valued at less than $20 billion. That represents a valuation of less than half of what Musk paid for the company back in 2022.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/01/43277294/visa-stock-moves-higher-as-company-becomes-first-partner-of-musks-xmoney-whats-going-on">Visa Stock Moves Higher As Company Becomes First Partner Of Musk&#8217;s XMoney: What&#8217;s Going On?</a></li>
</ul>
Image: Shutterstock

Social Media

Asset Sales

Twitter Blue Bird Logo From HQ Up For Auction: Here's How Much Social Media History Could Set You Back

Speculators are dialing back expectations for Federal Reserve interest rate cuts in 2025 ahead of the March Federal Open Market Committee meeting, as inflation concerns cast doubt on the central bank's <a href="https://www.benzinga.com/government/regulations/25/03/44364688/feds-march-meeting-expected-to-signal-no-hurry-on-rate-cuts-as-powell-likely-to-tread-carefully">willingness to ease policy.</a>
Data from Kalshi, a CFTC-regulated betting platform, indicates that traders are shifting bets toward fewer than three rate cuts. 
The most favored scenario now anticipates two cuts, carrying a 24% implied probability. Notably, the likelihood of just one rate cut jumped seven percentage points in a single day to 19%.
Betting-implied odds currently indicate that the most preferred outcome among retail bettors is two rate cuts at a 24% implied chance.
The Fed's December &#8220;dot plot&#8221; signaled a median expectation for two rate cuts in 2025, a downgrade from the four cuts it had projected in September. 
While retail bettors have turned more cautious, broader financial markets remain slightly more optimistic. Fed funds futures, tracked by the CME FedWatch tool, fully price in three rate cuts by December 2024, with a 35% probability of a fourth cut. 
This discrepancy suggests that institutional investors may still believe in a more accommodative Fed policy than retail traders do.
<iframe loading="lazy" src="https://kalshi.com/external-widgets/events/KXRATECUTCOUNT-25DEC31?color_scheme=light&#038;widget_size=large&#038;utm_campaign=benzinga_widget" width="552px" height="400px" style="border:0"></iframe>
<h3 class="wp-block-heading">What's Driving The Shift?</h3>
One factor weighing on rate-cut expectations is the risk that the Fed could revise inflation projections higher, particularly in response to higher trade tariffs mandated by President Donald Trump. 
December, the central bank had already raised its 2025 inflation forecast, projecting headline Personal Consumption Expenditures inflation at 2.5%, up from 2.1% in September. Core PCE inflation, which excludes food and energy prices, was also revised up to 2.5% from 2.2%.
According to both Bank of America and Goldman Sachs estimates, inflation estimates could be upwardly revised to 2.7% on Wednesday. 
Betting-implied odds tracked by Kalshi reveal that speculators expect inflation to average 3% in 2025. 
<iframe loading="lazy" src="https://kalshi.com/external-widgets/events/KXACPI-2025?color_scheme=light&#038;widget_size=large&#038;utm_campaign=benzinga_widget" width="552px" height="400px" style="border:0"></iframe>
<h3 class="wp-block-heading">A Dovish Tilt Or Continued Caution?</h3>
Federal Reserve Chair Jerome Powell has maintained a wait-and-see stance. Last week, he reiterated that the Fed does not need to rush into rate changes, reinforcing the need for more economic clarity before making any moves.
The consensus among economists is that the Fed will hold rates steady at 4.25%-4.50% at this week's meeting. Betting markets imply a near-unanimous probability of no change, but the focus will be on the Fed's revised economic outlook.
"The Fed will most likely indicate they remain data dependent," Chris Fasciano, chief market strategist at Commonwealth Financial Network, said in an email.
"Considering the better-than-expected CPI and PPI data released last week, if this trend continues it should allow the Fed to continue their rate cut path later in the year."
"The US Federal Reserve is widely expected to stay put this month. The market's focus will be on the guidance and the updated FOMC forecast," said Julien Lafargue, chief market strategist at Barclays Private Bank and Wealth Management.
He added that the Fed's projections may reflect weaker GDP growth, but the dot plot is unlikely to show a major shift.
The U.S. dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – fell to a six-month low on Tuesday, as fears over U.S. economic performance persist among investors. 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44379453/equity-exposure-plummets-cash-holdings-jump-as-investors-rethink-us-exceptionalism-bank-of-america-survey">Equity Exposure Plummets, Cash Holdings Jump As Investors Rethink &#8216;US Exceptionalism,&#8217; Bank Of America Survey</a></li>
</ul>
Photo: Shutterstock

Econ #s

Economics

Federal Reserve

PowerShares DB US Dollar Index Bullish Fund

Speculators Trim 2025 Rate-Cut Bets Ahead Of March Fed Meeting As Inflation Risks Rise

Press Releases

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Publishes 2024 Annual Report

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Comments

Genmab

뉴스

파트너 / 기고자

벤징가 글로벌